Britta Anker Bak

Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus

Athena Philis‐Tsimikas, K. Astamirova, Yashdeep Gupta et al. · Diabetes Research and Clinical Practice · 2018 · 40 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +16

Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials

J. Hans DeVries, Timothy S. Bailey, Anuj Bhargava et al. · Diabetes Obesity and Metabolism · 2018 · 22 citations · Full text

Medicine, Endocrinology, Pharmacology +16

Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478)

Athena Philis‐Tsimikas, Irene Stratton, Lone Troelsen et al. · Journal of Diabetes Science and Technology · 2019 · 22 citations · Full text

Medicine, Endocrinology, Pharmacology +15

High dimensional classifiers in the imbalanced case

Britta Anker Bak, Jens Ledet Jensen · Computational Statistics & Data Analysis · 2015 · 11 citations · Full text

Computing, Computer Science, Data Mining +13